Swathi Kaliki1, Carol L Shields2, Ralph C Eagle3, Geeta K Vemuganti4, Ana Almeida5, Fairooz P Manjandavida5, Kaustubh Mulay6, Santosh G Honavar7, Jerry A Shields5. 1. Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania; The Department of Pathology, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania; Ocular Oncology Service, Hyderabad, India. 2. Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania. Electronic address: carol.shields@shieldsoncology.com. 3. The Department of Pathology, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania. 4. The Department of Pathology, L. V. Prasad Eye Institute, Hyderabad, India; The Department of Pathology, University of Hyderabad, Hyderabad, India. 5. Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania. 6. The Department of Pathology, L. V. Prasad Eye Institute, Hyderabad, India. 7. Ocular Oncology Service, Hyderabad, India.
Abstract
PURPOSE: To describe the clinical features, histopathology, treatment, and outcomes of ciliary body medulloepithelioma. DESIGN: Retrospective study. PARTICIPANTS: Forty-one patients with medulloepithelioma. INTERVENTION: Cryotherapy, plaque radiotherapy, external beam radiotherapy, tumor removal by partial lamellar sclerouvectomy (PLSU), or enucleation. MAIN OUTCOME MEASURES: Metastasis and death. RESULTS: Of 41 patients with ciliary body medulloepithelioma, the median age at diagnosis was 5 years. The mean tumor basal diameter was 11 mm, and the mean tumor thickness was 7 mm. Related features included secondary glaucoma (n = 18, 44%), iris neovascularization (n = 21, 51%), cataract (n = 19, 46%), lens subluxation (n = 11, 27%), lens coloboma (n = 8, 20%), retrolental neoplastic cyclitic membrane (n = 21, 51%), intratumoral cysts (n = 25, 61%), and extraocular extension (n = 4, 10%). There was systemic association with pleuropulmonary blastoma in 2 cases (5%). Primary tumor treatment included enucleation (n = 21, 60%), tumor removal by PLSU (n = 8, 23%), plaque radiotherapy (n = 3, 9%), external beam radiotherapy (n = 1, 3%), cryotherapy (n = 1, 3%), or palliative chemotherapy (n = 1, 3%). In 1 case, medulloepithelioma was diagnosed histopathologically after inadvertent evisceration for blind painful eye. Subsequent treatment for residual or recurrent tumor in cases treated conservatively/inappropriately (n = 15) was necessary in 7 cases (47%). Histopathology disclosed benign features in 6 cases (20%), malignant features in 24 cases (80%), teratoid features in 11 cases (37%), and nonteratoid features in 19 cases (63%). In the 26 enucleated eyes, other features included retrolental neoplastic cyclitic membrane (n = 18, 69%), neoplastic epiretinal membrane (n = 6, 23%), and persistent hyaloid artery (n = 6, 23%). Systemic metastasis occurred in 3 cases (8%) over a mean follow-up of 49 months, all of whom presented with extrascleral extension of tumor due to mean delay in diagnosis by 39 months. CONCLUSIONS: Medulloepithelioma most commonly occurs in children. Systemic association with pleuropulmonary blastoma rarely is found. Patients with extrascleral medulloepithelioma are at risk for metastasis.
PURPOSE: To describe the clinical features, histopathology, treatment, and outcomes of ciliary body medulloepithelioma. DESIGN: Retrospective study. PARTICIPANTS: Forty-one patients with medulloepithelioma. INTERVENTION: Cryotherapy, plaque radiotherapy, external beam radiotherapy, tumor removal by partial lamellar sclerouvectomy (PLSU), or enucleation. MAIN OUTCOME MEASURES: Metastasis and death. RESULTS: Of 41 patients with ciliary body medulloepithelioma, the median age at diagnosis was 5 years. The mean tumor basal diameter was 11 mm, and the mean tumor thickness was 7 mm. Related features included secondary glaucoma (n = 18, 44%), iris neovascularization (n = 21, 51%), cataract (n = 19, 46%), lens subluxation (n = 11, 27%), lens coloboma (n = 8, 20%), retrolental neoplastic cyclitic membrane (n = 21, 51%), intratumoral cysts (n = 25, 61%), and extraocular extension (n = 4, 10%). There was systemic association with pleuropulmonary blastoma in 2 cases (5%). Primary tumor treatment included enucleation (n = 21, 60%), tumor removal by PLSU (n = 8, 23%), plaque radiotherapy (n = 3, 9%), external beam radiotherapy (n = 1, 3%), cryotherapy (n = 1, 3%), or palliative chemotherapy (n = 1, 3%). In 1 case, medulloepithelioma was diagnosed histopathologically after inadvertent evisceration for blind painful eye. Subsequent treatment for residual or recurrent tumor in cases treated conservatively/inappropriately (n = 15) was necessary in 7 cases (47%). Histopathology disclosed benign features in 6 cases (20%), malignant features in 24 cases (80%), teratoid features in 11 cases (37%), and nonteratoid features in 19 cases (63%). In the 26 enucleated eyes, other features included retrolental neoplastic cyclitic membrane (n = 18, 69%), neoplastic epiretinal membrane (n = 6, 23%), and persistent hyaloid artery (n = 6, 23%). Systemic metastasis occurred in 3 cases (8%) over a mean follow-up of 49 months, all of whom presented with extrascleral extension of tumor due to mean delay in diagnosis by 39 months. CONCLUSIONS: Medulloepithelioma most commonly occurs in children. Systemic association with pleuropulmonary blastoma rarely is found. Patients with extrascleral medulloepithelioma are at risk for metastasis.
Authors: John A Ozolek; Debra E Cohen; Marcel Kool; Stefan M Pfister; Andrey Korshunov; Andrew J Bukowinski; Amy W Davis Journal: CNS Oncol Date: 2015-06-29
Authors: Morgan L Shannon; Ryann M Fame; Kevin F Chau; Neil Dani; Monica L Calicchio; Gwenaelle S Géléoc; Hart G W Lidov; Sanda Alexandrescu; Maria K Lehtinen Journal: Am J Pathol Date: 2018-03-13 Impact factor: 4.307
Authors: Laryssa A Huryn; Amy Turriff; Laura A Harney; Ann Garrity Carr; Patricia Chevez-Barrios; Dan S Gombos; Radha Ram; Robert B Hufnagel; D Ashley Hill; Wadih M Zein; Kris Ann P Schultz; Rachel Bishop; Douglas R Stewart Journal: Ophthalmology Date: 2018-10-17 Impact factor: 12.079
Authors: Deepak P Edward; Hind Alkatan; Qundeel Rafiq; Charles Eberhart; Saleh Al Mesfer; Nicola Ghazi; Leen Al Safieh; Altaf A Kondkar; Khaled K Abu Amero Journal: PLoS One Date: 2015-03-25 Impact factor: 3.240